REVIEWS |
|
E.O. Golubenko, M.I. Savelyeva, I.V. Poddubnaya, V.V. Korennaya
Possibilities of a pharmacogenetic approach to solving gynecological problems in patients taking tamoxifen: a literature review
|
6-12 |
|
Sh.G. Khakimova, A.D. Zikiryakhodzhaev, A.D. Kaprin, G.G. Khakimova, I.M. Onofriychuk, E.A. Rasskazova, A.S. Sukhotko, M.Yu. Vlasova, A.R. Bosieva, V.K. Tokaev
Reconstructive plastic surgery of the breast using autogenous tissue. Historical aspects
|
14-19 |
|
E.A. Ulrikh
Venous thrombosis and malignant gynecological diseases: the place of direct oral anticoagulants in prevention
|
20-23 |
|
|
G.A. Dashyan, V.V. Konstantinova, E.S. Dzhelialov, R.M. Akhmedov, Yu.V. Semiletova, A.S. Zhurov, A.E. Tyusenko, A.A. Olchonova, I.A. Pavlikova, A.M. Belousov
Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences
|
24-30 |
ORIGINAL ARTICLES |
|
T.N. Trofimtseva, S.K. Yarovoy, A.A. Gritskevich, T.P. Baytman
Efficacy of the combination of pembrolizumab and axitinib in the treatment of renal cell carcinoma associated with chronic kidney disease
|
31-36 |
|
D.A. Gavrilova, N.S. Besova, E.S. Obarevich, G.G. Makiev, A.A. Tryakin, I.S. Stilidi
Prospective randomized phase III trial comparing FOLFIRINOX and mFOLFOX6 as first-line treatment for patients with disseminated gastric cancer: interim assessment of tolerability and toxicity
|
37-43 |
|
M.O. Bagova, Y.K. Mangasarova, A.U. Magomedova, O.V. Margolin, E.S. Nesterova, L.G. Gorenkova, R.R. Abdurashidova, Yu.A. Chabaeva, I.V. Galtseva, I.M. Nakastoev, V.S. Galuzyak, O.N. Bayteryakova, A.A. Shcherbakova, M.A. Telyashov, V.K. Spitsyn, D.A. Sukhorukov, E.E. Zvonkov
Mobilization of hematopoietic blood stem cells using the drug empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases
|
44-50 |
|
A.A. Gritskevich, V.A. Okhanyan, D.M. Monakov, A.D. Simonov, A.G. Kochetov, N.A. Karelskaya, Zh. Polotbek, I.G. Rusakov
Short-term and long-term results of robot-assisted cystectomy with various types of urine derivation in patients with urothelial carcinoma of the bladder
|
52-59 |
|
I.S. Gulian, E.P. Bystritskaya, N.Yu. Otstavnykh, E.V. Khudchenko, E.V. Eliseeva, V.I. Apanasevich, M.P. Isaeva
GSTT1 and GSTM1 deletion polymorphism as a predictor of response to hormonal therapy for breast cancer
|
60-64 |
|
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
|
66-71 |
|
N.S. Besova, E.S. Obarevich, A.A. Tryakin, D.A. Gavrilova, S.N. Nered, A.E. Kalinin, I.S. Stilidi
Conversion therapy for disseminated gastric cancer. Interim results of a retrospective analysis of our own data
|
72-86 |
|
T.N. Trofimtseva, S.K. Yarovoy, A.A. Gritskevich
Prevalence of chronic kidney disease among cancer patients
|
88-93 |
|
|
G.A. Dashyan, E.S. Dzhelialov, V.V. Konstantinova, Yu.A. Gronskaya, A.D. Murskikh, R.M. Akhmedov, A.E. Tyusenko, A.A. Olchonova, Z.V. Dyakonenko, O.A. Sereda, A.M. Belousov
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
|
94-100 |
|
O.O. Gordeeva, K.A. Ivanova, A.A. Meshcheryakov
Ceritinib in the treatment of ALK-positive non-small cell lung cancer
|
102-107 |
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.O. Gorina, A.V. Komyakhov, R.M. Paltuev, T.T. Tabagua, S.S. Ereshenko
Trastuzumab deruxtecan in the treatment of breast cancer
|
109-112 |
|
A.A. Gritskevich, T.P. Byteman, D.M. Monakov, I.G. Rusakov, S.V. Mishugin
PARP inhibitors in a personalized approach to the treatment of castration-resistant prostate cancer: clinical case
|
113-118 |
|
G.G. Khakimova, M.B. Tashtemirova, A.N. Rakhmonov, M.A. Zhakhongirova
Clinical case of a rare solid pseudopapillary tumor of the pancreas
|
120-124 |
Русский
